{"id":34806,"date":"2024-02-22T10:06:52","date_gmt":"2024-02-22T09:06:52","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=34806"},"modified":"2024-02-16T15:09:50","modified_gmt":"2024-02-16T14:09:50","slug":"update-inhibitoren-der-proproteinkonvertase-subtilisin-kexin-typ-9-pcsk9i-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2024\/update-inhibitoren-der-proproteinkonvertase-subtilisin-kexin-typ-9-pcsk9i-cme","title":{"rendered":"Update: Inhibitoren der Proproteinkonvertase Subtilisin\/Kexin Typ 9 (PCSK9i) [CME]"},"content":{"rendered":"<p>Im Jahr 2015 wurden die humanen monoklonalen Antik\u00f6rper (mAK) Evolocumab und Alirocumab zur Behandlung der Hypercholesterin\u00e4mie zugelassen und 5\u00a0Jahre sp\u00e4ter Inclisiran aus der Gruppe der \u201esmall interfering RNA\u201c (siRNA; vgl.\u00a0). Die beiden mAK k\u00f6nnen verordnet werden zur Behandlung der prim\u00e4ren Hypercholesterin\u00e4mie und der gemischten Dyslipid\u00e4mie bei Erwachsenen und Kindern und Jugendlichen im Alter von \u2265\u00a08 [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im Jahr 2015 wurden die humanen monoklonalen Antik\u00f6rper (mAK) Evolocumab und Alirocumab zur Behandlung der Hypercholesterin\u00e4mie zugelassen und 5\u00a0Jahre sp\u00e4ter Inclisiran aus der Gruppe der \u201esmall interfering RNA\u201c (siRNA; vgl.\u00a0). Die beiden mAK k\u00f6nnen verordnet werden zur Behandlung der prim\u00e4ren Hypercholesterin\u00e4mie und der gemischten Dyslipid\u00e4mie bei Erwachsenen und Kindern und Jugendlichen im Alter von \u2265\u00a08 [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1518,1272,1274,3064,3065,4869,5962,453,5638,5963,456,5964,5965,1525,1526,1522,5961],"class_list":["post-34806","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-alirocumab","tag-arteriosklerose","tag-cholesterin","tag-descartes-studie","tag-evolocumab","tag-fourier-studie","tag-glagov-studie","tag-hypercholesterinaemie","tag-inclisiran","tag-laplace-timi-57-studie","tag-lipidsenker","tag-odyssey-studie","tag-orion-studie","tag-pcsk9","tag-pcsk9-antikoerper","tag-pcsk9-hemmer","tag-pcsk9-inhibitoren"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/34806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=34806"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/34806\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=34806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=34806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=34806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}